Equity Investing
Metacrine, Inc. (MTCR) stock falls around 49.87% in aftermarket – Here’s why?
Metacrine, Inc. (MTCR) experienced a decline of 49.87% in the aftermarket because the company released Interim Results for the MET642 Phase 2a Trial. However, the